Risk-adjusted therapy of acute lymphoblastic leukemia can decrease treatment burden and improve survival: treatment results of 2 169 unselected pediatric and adolescent patients enrolled in the trial ALL-BFM 95 - Möricke, A; Reiter, A; Zimmermann, M German-Austrian-Swiss ALL-BFM Study Group (Blood, 2008)
et al.